Skip to main content
. 2018 Apr 11;11:54. doi: 10.1186/s13045-018-0579-3

Fig. 1.

Fig. 1

Exosomal miR-122 from adipose tissue-derived mesenchymal stem cells (AMSCs) could inhibit the proliferation of recipient HepG2 cells and enhance HCC chemosensitivity in vivo. This diagram shows the experimental platform that has been tested using HepG2 cells to modulate their sensitivity to chemotherapeutics